[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539203":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":32,"centralContacts":33,"locations":40,"responsibleParty":57,"collaborators":32,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":32,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":43,"whyStopped":32,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nice","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"CKD group","EXPERIMENTAL","Patient with chronic kidney disease",[13],"Other: PPI and T50 dosing",{"label":15,"type":10,"description":16,"interventionNames":17},"Dialysis group","Dialysis patients (hemodialysis or peritoneal dialysis)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"kidney transplant group","Kidney transplant patients",[13],{"label":23,"type":24,"description":25,"interventionNames":26},"Control group","ACTIVE_COMPARATOR","Control group of patients with normal renal function",[13],[28],{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"PPI and T50 dosing","Sampling for PPI determination and T50 in blood and urine.",[9,23,15,19],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Julie BERNARDOR","CONTACT","04.92.03.63.65","+33","bernardor.j@chu-nice.fr",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"CHU Nice - Hôpital de l'Archet 2","RECRUITING","Nice","Alpes-Maritimes","06200","France","FR",{"type":50,"coordinates":51},"Point",[52,53],7.26608,43.70313,{"lat":53,"lon":52},[56],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},{"type":58,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100539203","inorganic-pyrophosphate-homeostasis-ppi-in-pediatric-chronic-kidney-disease-100539203",false,"NCT06300788","Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease","Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease - PPi-DIA","PPi-DIA","Inclusion Criteria:\n\nAll groups :\n\n* Minor patients (\\\u003C18 years)\n* Patients of both sexes\n* Informed patients and parents who have signed the informed consent form\n* Patients affiliated to social security\n\nControl group :\n\n\\- Patients with no particular pathology undergoing surgery and receiving a preoperative check-up\n\nCKD groups :\n\n* Patients on dialysis for more than 3 months, regardless of technique\n* Kidney transplant patients\n* Patients with CKD, whatever the cause\n\nExclusion Criteria:\n\n* Progressive cancer or kidney disease\n* Treatments that may modify PPi concentration (e.g. bisphosphonates)","ALL","0 Years","18 Years",{"count":71,"type":72},60,"ESTIMATED","INTERVENTIONAL",[75],"NA","The investigator aim to identify the role of inorganic pyrophosphate and other anti-calcifying molecules in vascular disease in children with chronic kidney disease, with a view to developing therapeutic approaches aimed at limiting the onset of vasculopathy.",[78],"Pyrophosphate, Fetuin A, IL1, IL6, TNFalpha, Control",[80],"Pyrophosphate","2026-07-24",{"date":83,"type":84},"2026-07-27","ACTUAL",{"date":86,"type":84},"2024-05-27",{"date":88,"type":72},"2027-11-27",{"name":5,"class":6},1]